⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VTVT News
vTv Therapeutics Inc. Class A Common Stock
vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery Systems
globenewswire.com
VTVT
iOnctura appoints Paul Sekhri as Chair of its Board of Directors
globenewswire.com
APMD
VTVT
VEEV
vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026
globenewswire.com
VTVT
vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease
globenewswire.com
VTVT
Form 8-K
sec.gov
VTVT
vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026
globenewswire.com
VTVT
vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)
globenewswire.com
VTVT
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
VTVT
vTv Therapeutics to Participate in September Investor Conferences
globenewswire.com
VTVT
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
VTVT